A 1% improvement on ADT's plan is worth
~$2.2M / year
Asymmetric risk, measurable upside — exactly the kind of line analytics should own.
Total annual plan spend
~$219M
~12,500 employees × $17,496 national avg cost.
Estimated oncology spend
~$52M
23.9% of plan spend, growing with no matching outcome gain.
Single-claim exposure
$4.3M
Highest single cancer claim in 2024 — one event on a self-funded plan.
The analytics layer for your oncology spend
A field-services workforce skews older — raising the incidence of high-cost cancers and the odds of a catastrophic claim. The problem isn't just the spend; it's that most plans can't see where it's leaking until the claim has landed.
ClearOnc is Moffitt-powered navigation with the reporting to prove it. Site-of-care and specialty-drug routing, biomarker-appropriate therapy, survivorship adherence — and the dashboard that lets you track every one:
Avoided admissionsER and inpatient events prevented through early navigation.
Biomarker-appropriate %Share of members on therapy matched to their tumor profile.
Survivorship adherenceCare-plan completion that cuts recurrence and absenteeism cost.
Where the 1% hides
The gaps the claims data won't surface on its own — each one is something ClearOnc closes.
11 of 20
costliest injectable drugs treat cancer — specialty-drug routing is where dollars leak.
8%
of lung-cancer patients get full NCCN biomarker testing — so plans fund therapies that can't work.
1 in 3
cancer patients ever get a survivorship care plan — driving avoidable recurrence cost.
7–9%
annual cost growth with no outcome gain — a 13-year high you can't analyze away.
20 minutes, before your August renewal
We'll pull ADT's actual oncology exposure and the metrics to track it.
Book your oncology spend review → Run your full breakdown